2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Meghan Thompson, MD, discusses the rationale for the phase 1/2 BRUIN study in patients with Richter transformation.
Meghan Thompson, MD, third-year fellow, Hematology and Medical Oncology, Memorial Sloan Kettering Cancer Center, discusses the rationale for the phase 1/2 BRUIN study (NCT03740529) in patients with Richter transformation.
Richter transformation is a rare, but serious complication that arises in a small subgroup of patients with CLL, Thompson says. Moreover, the disease can transform into a more aggressive lymphoma, such as diffuse large B-cell lymphoma or Hodgkin lymphoma, Thompson adds. Patients with Richter transformation are considered high risk and have an estimated overall survival ofbetween 3 and 11 months, Thompson explains.
Moreover, the standard of care treatment is not clear for these patients, Thompson continues. However, the BRUIN study evaluated a novel approach to treating patients with Richter transformation with pirtobrutinib (LOXO-305), Thompson concludes.